Screener
Sutro Biopharma STRO Q3 2026 earnings
Reported November 12, 2026 · After market close
Revenue$9.1MMiss by $5.0M
EPS-$1.90Miss by $0.26
Revenue estimate$14.1M
EPS estimate-$1.64
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027. Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs. Together these advances reflect our proficiency in translating platform innovation into a growing pipeline of therapies designed to improve patient outcomes and create long-term value.”
Next report
Date not yet announcedValuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Sutro Biopharma report Q3 2026 earnings?
- Sutro Biopharma (STRO) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Sutro Biopharma's Q3 2026 revenue and EPS?
- Sutro Biopharma reported revenue of $9.1M and eps of $-1.90 for Q3 2026.
- Did Sutro Biopharma beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $14.1M by $5.0M. EPS missed the consensus estimate of $-1.64 by $0.26.
- How did Sutro Biopharma's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 6.1% from $9.7M a year earlier and eps grew 71.6% from $-6.70.
- Where can I find Sutro Biopharma's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-458641) and the 10-Q periodic report (0001193125-26-458680) directly on SEC EDGAR. The filing index links above go to sec.gov.
